dorzolamide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
949 120279-96-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • dorzolamide
  • dorzolamide hydrochloride
  • dorzolamide HCl
topically effective ocular hypotensive carbonic anhydrase inhibitor; RN refers to mono-HCl (4S-trans)-isomer
  • Molecular weight: 324.43
  • Formula: C10H16N2O4S3
  • CLOGP: 0.15
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 2
  • TPSA: 106.33
  • ALOGS: -2.67
  • ROTB: 3
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.30 ml None

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 14 mg/mL Bocci G, Oprea TI, Benet LZ
EoM (Fraction excreted unchanged in urine) 10 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 3.08 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2B,AXL,BRAF,CAMK2D,CDK5,CDK9,EIF2AK3,ERBB2,GRK2,ITK,MAPK10,MAPK7,NTRK2,PDK1,PDK2,PDK4,PIK3CA,PIK3CB,PRKDC,TEK 20
kinase-selectivity-class AXL,GRK2,MAP2K6,PDK1,TEK,ZAP70 6
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

DateAgencyCompanyOrphan
Dec. 9, 1994 FDA MERCK

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Intraocular pressure increased 341.21 15.92 88 8586 7005 90612768
Eye irritation 281.24 15.92 110 8564 33868 90585905
Treatment failure 256.33 15.92 220 8454 303708 90316065
Ocular hyperaemia 145.64 15.92 69 8605 33729 90586044
Eye pain 145.21 15.92 75 8599 44093 90575680
Glaucoma 126.49 15.92 54 8620 20701 90599072
Visual acuity reduced 110.76 15.92 51 8623 23359 90596414
Choroidal effusion 91.68 15.92 20 8654 769 90619004
Product quality issue 84.52 15.92 66 8608 79259 90540514
Product container issue 71.48 15.92 20 8654 2161 90617612
Product delivery mechanism issue 70.80 15.92 15 8659 501 90619272
Corneal oedema 69.52 15.92 19 8655 1882 90617891
Ocular surface disease 69.26 15.92 11 8663 67 90619706
Product packaging quantity issue 58.53 15.92 16 8658 1586 90618187
No adverse event 56.54 15.92 49 8625 67933 90551840
Burns second degree 55.18 15.92 16 8658 1964 90617809
Catarrh 53.62 15.92 15 8659 1619 90618154
Hypotony of eye 51.30 15.92 10 8664 218 90619555
Choroidal detachment 48.94 15.92 10 8664 279 90619494
Steroid dependence 48.76 15.92 15 8659 2254 90617519
Vision blurred 43.18 15.92 53 8621 110240 90509533
Iridocyclitis 41.71 15.92 15 8659 3646 90616127
Hypopnoea 38.92 15.92 15 8659 4416 90615357
Bradycardia 37.28 15.92 43 8631 83804 90535969
Visual impairment 37.06 15.92 54 8620 132311 90487462
Gingival pain 36.39 15.92 18 8656 9634 90610139
Accidental overdose 35.57 15.92 26 8648 28247 90591526
Product dose omission issue 35.53 15.92 83 8591 291604 90328169
Superficial injury of eye 34.66 15.92 8 8666 398 90619375
Iritis 34.25 15.92 13 8661 3673 90616100
Glaucoma surgery 33.49 15.92 6 8668 81 90619692
Trabeculectomy 31.41 15.92 5 8669 31 90619742
Hyphaema 30.12 15.92 7 8667 359 90619414
Thermal burns of eye 29.34 15.92 6 8668 168 90619605
Punctate keratitis 29.31 15.92 8 8666 788 90618985
Cataract 28.78 15.92 35 8639 72057 90547716
Erythema of eyelid 28.43 15.92 11 8663 3272 90616501
Eye pruritus 28.42 15.92 23 8651 29004 90590769
Foreign body sensation in eyes 28.38 15.92 11 8663 3289 90616484
Ulcerative keratitis 27.89 15.92 11 8663 3442 90616331
Acute generalised exanthematous pustulosis 27.88 15.92 17 8657 13686 90606087
Conjunctival follicles 27.23 15.92 4 8670 13 90619760
Dysgeusia 26.87 15.92 29 8645 52531 90567242
Angle closure glaucoma 26.56 15.92 10 8664 2765 90617008
Impaired quality of life 26.24 15.92 20 8654 23124 90596649
Retinal disorder 26.22 15.92 9 8665 1910 90617863
Parosmia 26.11 15.92 13 8661 7056 90612717
Joint swelling 25.90 15.92 8 8666 503292 90116481
Rhinitis 25.49 15.92 16 8658 13556 90606217
Swollen tongue 24.62 15.92 26 8648 45930 90573843
Conjunctival erosion 23.84 15.92 5 8669 159 90619614
Blindness 23.81 15.92 20 8654 26548 90593225
Conjunctivitis 23.72 15.92 20 8654 26686 90593087
Genital erythema 23.52 15.92 4 8670 39 90619734
Lacrimation increased 23.49 15.92 20 8654 27042 90592731
Eye disorder 23.28 15.92 20 8654 27370 90592403
Hypoglycaemia 23.28 15.92 31 8643 69817 90549956
Visual field defect 23.04 15.92 12 8662 7154 90612619
Tinnitus 22.41 15.92 24 8650 43078 90576695
Conjunctival scar 22.33 15.92 4 8670 54 90619719
Intraocular pressure test abnormal 22.20 15.92 5 8669 223 90619550
Abnormal sensation in eye 22.17 15.92 8 8666 1963 90617810
Maternal exposure during pregnancy 21.90 15.92 4 8670 360059 90259714
Conjunctival hyperaemia 21.82 15.92 9 8665 3160 90616613
Eye discharge 21.44 15.92 12 8662 8246 90611527
Ocular discomfort 21.44 15.92 11 8663 6359 90613414
Palpitations 21.29 15.92 43 8631 136685 90483088
Cardiac murmur 21.24 15.92 16 8658 18178 90601595
Intraocular pressure fluctuation 21.20 15.92 4 8670 73 90619700
Conjunctivitis allergic 21.17 15.92 7 8667 1325 90618448
Nightmare 20.81 15.92 17 8657 21708 90598065
Intraocular lens implant 19.51 15.92 5 8669 386 90619387
Rectal haemorrhage 19.26 15.92 31 8643 82713 90537060
Conjunctival oedema 19.11 15.92 6 8668 963 90618810
Infusion related reaction 19.10 15.92 8 8666 416772 90203001
Eye complication associated with device 19.07 15.92 3 8671 17 90619756
Retinal vascular occlusion 18.92 15.92 5 8669 436 90619337
Glossodynia 18.67 15.92 4 8670 321775 90297998
Uveitis 18.60 15.92 14 8660 15889 90603884
Corneal neovascularisation 18.51 15.92 4 8670 147 90619626
Impaired work ability 18.26 15.92 15 8659 19311 90600462
Device deposit issue 17.96 15.92 3 8671 26 90619747
Product package associated injury 17.57 15.92 3 8671 30 90619743
Wound 17.11 15.92 4 8670 302976 90316797
Arthropathy 16.82 15.92 7 8667 366235 90253538
Urine output decreased 16.78 15.92 12 8662 12591 90607182
Blepharitis 16.75 15.92 8 8666 3968 90615805
Thyroxine decreased 16.74 15.92 5 8669 680 90619093
Iris hyperpigmentation 16.64 15.92 3 8671 42 90619731
Bronchiectasis 16.38 15.92 15 8659 22315 90597458
Acute lymphocytic leukaemia 16.00 15.92 7 8667 2841 90616932
Accidental exposure to product 15.99 15.92 20 8654 42346 90577427

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Intraocular pressure increased 265.61 21.43 87 10147 6346 42604755
Burns second degree 241.85 21.43 80 10154 6016 42605085
Catarrh 239.26 21.43 79 10155 5907 42605194
Steroid dependence 234.18 21.43 80 10154 6642 42604459
Parosmia 223.64 21.43 80 10154 7611 42603490
Hypopnoea 221.72 21.43 80 10154 7802 42603299
Gingival pain 215.88 21.43 80 10154 8414 42602687
Systemic lupus erythematosus 208.62 21.43 80 10154 9244 42601857
Rhinitis 192.56 21.43 81 10153 11896 42599205
Treatment failure 188.16 21.43 140 10094 62484 42548617
Impaired work ability 185.17 21.43 79 10155 12012 42599089
Cardiac murmur 184.25 21.43 80 10154 12695 42598406
Bronchiectasis 169.78 21.43 84 10150 17935 42593166
Eye irritation 163.61 21.43 71 10163 11247 42599854
Swollen tongue 156.77 21.43 84 10150 21147 42589954
Frequent bowel movements 153.32 21.43 83 10151 21324 42589777
Alcohol poisoning 151.76 21.43 60 10174 7514 42603587
Impaired quality of life 145.27 21.43 70 10164 14107 42596994
Nightmare 143.90 21.43 84 10150 24928 42586173
Migraine 137.43 21.43 82 10152 25332 42585769
Colitis ulcerative 135.19 21.43 82 10152 26093 42585008
Tinnitus 135.10 21.43 85 10149 28853 42582248
Eczema 131.89 21.43 89 10145 33997 42577104
Dysgeusia 131.65 21.43 89 10145 34100 42577001
Accidental overdose 129.21 21.43 82 10152 28248 42582853
Medication error 126.92 21.43 86 10148 33068 42578033
Vertigo 121.82 21.43 85 10149 34262 42576839
Eye pain 119.06 21.43 65 10169 16965 42594136
Tubulointerstitial nephritis 116.41 21.43 80 10154 31468 42579633
Arthritis 115.08 21.43 89 10145 41976 42569125
Stress 109.03 21.43 88 10146 44124 42566977
Rectal haemorrhage 104.22 21.43 90 10144 49516 42561585
Palpitations 94.44 21.43 86 10148 50711 42560390
Haematochezia 93.45 21.43 91 10143 58345 42552756
Loss of personal independence in daily activities 91.94 21.43 84 10150 49732 42561369
Inappropriate schedule of product administration 79.20 21.43 106 10128 95796 42515305
Visual acuity reduced 73.08 21.43 48 10186 17502 42593599
Adverse drug reaction 72.74 21.43 65 10169 37369 42573732
Deep vein thrombosis 68.06 21.43 88 10146 76869 42534232
Intentional product use issue 68.04 21.43 85 10149 71748 42539353
Abdominal discomfort 68.04 21.43 87 10147 75168 42535933
Cerebrovascular accident 67.71 21.43 99 10135 97061 42514040
Ocular hyperaemia 67.30 21.43 44 10190 15919 42595182
Corneal oedema 64.11 21.43 21 10213 1527 42609574
Depression 54.97 21.43 97 10137 111266 42499835
Ocular surface disease 54.89 21.43 11 10223 104 42610997
Pain in extremity 52.20 21.43 113 10121 150491 42460610
Confusional state 50.57 21.43 119 10115 167478 42443623
Blepharitis 48.32 21.43 18 10216 1915 42609186
Glaucoma 45.55 21.43 27 10207 8221 42602880
COVID-19 44.81 21.43 91 10143 115857 42495244
Product container issue 44.41 21.43 14 10220 900 42610201
Hyphaema 43.34 21.43 13 10221 707 42610394
Pulmonary embolism 41.70 21.43 90 10144 119522 42491579
Anterior chamber disorder 39.70 21.43 8 10226 78 42611023
Weight decreased 38.08 21.43 123 10111 207825 42403276
Product quality issue 36.61 21.43 32 10202 17850 42593251
Product delivery mechanism issue 35.60 21.43 9 10225 257 42610844
Product use in unapproved indication 34.57 21.43 110 10124 184346 42426755
Choroidal detachment 33.59 21.43 10 10224 530 42610571
Eye pruritus 33.04 21.43 25 10209 11387 42599714
Somnolence 32.95 21.43 91 10143 141014 42470087
Headache 32.21 21.43 128 10106 239241 42371860
Lacrimation increased 30.21 21.43 24 10210 11734 42599367
Scleral hyperaemia 28.95 21.43 6 10228 68 42611033
Product packaging quantity issue 28.08 21.43 11 10223 1342 42609759
Vision blurred 28.05 21.43 48 10186 53651 42557450
Ulcerative keratitis 26.61 21.43 12 10222 2076 42609025
Toxicity to various agents 26.41 21.43 11 10223 229125 42381976
Intraocular pressure test abnormal 26.21 21.43 6 10228 111 42610990
Congenital vas deferens absence 25.81 21.43 5 10229 39 42611062
Congenital muscle absence 25.81 21.43 5 10229 39 42611062
Rash 25.21 21.43 132 10102 276822 42334279
Pain 24.60 21.43 120 10114 244728 42366373
Iridocyclitis 22.88 21.43 11 10223 2200 42608901
Cardioactive drug level increased 22.19 21.43 10 10224 1727 42609374
Myopic chorioretinal degeneration 22.00 21.43 3 10231 0 42611101
No adverse event 21.86 21.43 36 10198 38985 42572116

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Intraocular pressure increased 453.30 16.82 131 15512 10745 110562911
Burns second degree 326.01 16.82 94 15549 7639 110566017
Catarrh 321.92 16.82 92 15551 7243 110566413
Steroid dependence 313.20 16.82 93 15550 8376 110565280
Hypopnoea 286.14 16.82 93 15550 11287 110562369
Parosmia 272.73 16.82 93 15550 13087 110560569
Gingival pain 264.11 16.82 95 15548 15641 110558015
Rhinitis 230.91 16.82 95 15548 22450 110551206
Cardiac murmur 219.50 16.82 94 15549 24534 110549122
Impaired work ability 200.31 16.82 90 15553 26329 110547327
Eye irritation 194.95 16.82 95 15548 33357 110540299
Bronchiectasis 192.97 16.82 97 15546 36396 110537260
Nightmare 190.08 16.82 98 15545 38765 110534891
Accidental overdose 182.12 16.82 105 15538 51729 110521927
Impaired quality of life 180.20 16.82 87 15556 29930 110543726
Alcohol poisoning 180.17 16.82 62 15581 8958 110564698
Swollen tongue 174.91 16.82 108 15535 60254 110513402
Tinnitus 164.53 16.82 104 15539 60436 110513220
Dysgeusia 157.90 16.82 107 15536 69878 110503778
Eczema 150.06 16.82 105 15538 72188 110501468
Visual acuity reduced 148.35 16.82 78 15565 32095 110541561
Tubulointerstitial nephritis 146.87 16.82 93 15550 54191 110519465
Frequent bowel movements 135.06 16.82 98 15545 71292 110502364
Vertigo 132.83 16.82 105 15538 86765 110486891
Eye pain 130.98 16.82 84 15559 50015 110523641
Rectal haemorrhage 128.24 16.82 118 15525 119715 110453941
Colitis ulcerative 123.65 16.82 96 15547 77267 110496389
Haematochezia 122.15 16.82 113 15530 115411 110458245
Corneal oedema 117.96 16.82 35 15608 3138 110570518
Ocular surface disease 112.93 16.82 20 15623 164 110573492
Medication error 109.33 16.82 102 15541 105264 110468392
Ocular hyperaemia 107.98 16.82 68 15575 39218 110534438
Stress 107.42 16.82 101 15542 105247 110468409
Palpitations 103.59 16.82 120 15523 159092 110414564
Deep vein thrombosis 90.26 16.82 105 15538 139782 110433874
Inappropriate schedule of product administration 89.05 16.82 126 15517 203511 110370145
Glaucoma 88.19 16.82 49 15594 22468 110551188
Cerebrovascular accident 83.48 16.82 115 15528 181169 110392487
Choroidal effusion 81.50 16.82 20 15623 870 110572786
Loss of personal independence in daily activities 74.89 16.82 99 15544 149921 110423735
Arthritis 73.70 16.82 104 15539 167482 110406174
Adverse drug reaction 71.04 16.82 81 15562 105478 110468178
Blepharitis 70.82 16.82 26 15617 4526 110569130
Choroidal detachment 63.91 16.82 16 15627 756 110572900
Confusional state 62.52 16.82 176 15467 468504 110105152
Migraine 57.68 16.82 94 15549 171558 110402098
Pulmonary embolism 55.88 16.82 105 15538 214369 110359287
Hyphaema 53.60 16.82 15 15628 1092 110572564
Product container issue 52.57 16.82 16 15627 1564 110572092
COVID-19 50.72 16.82 109 15534 244951 110328705
Somnolence 48.04 16.82 120 15523 297329 110276327
Product use in unapproved indication 44.73 16.82 152 15491 447225 110126431
Anterior chamber disorder 44.30 16.82 9 15634 162 110573494
Iridocyclitis 42.81 16.82 19 15624 5389 110568267
Depression 41.11 16.82 118 15525 317217 110256439
Intentional product use issue 41.05 16.82 101 15542 247805 110325851
Weight decreased 40.77 16.82 152 15491 467905 110105751
Trabeculectomy 39.35 16.82 7 15636 59 110573597
Ulcerative keratitis 38.55 16.82 17 15626 4749 110568907
Iritis 35.72 16.82 16 15627 4636 110569020
Vision blurred 34.62 16.82 64 15579 128958 110444698
Cataract 34.42 16.82 49 15594 79436 110494220
Visual field defect 34.27 16.82 20 15623 10052 110563604
Eye discharge 34.13 16.82 19 15624 8735 110564921
Pain in extremity 32.73 16.82 146 15497 486972 110086684
Systemic lupus erythematosus 31.41 16.82 93 15550 254245 110319411
Corneal neovascularisation 31.10 16.82 7 15636 208 110573448
Ocular hypertension 31.09 16.82 12 15631 2396 110571260
Corneal decompensation 30.95 16.82 6 15637 84 110573572
Intraocular pressure test abnormal 30.91 16.82 7 15636 214 110573442
Lacrimation increased 30.23 16.82 29 15614 30921 110542735
Floppy iris syndrome 27.63 16.82 7 15636 347 110573309
Nausea 27.34 16.82 87 15556 1235603 109338053
General physical health deterioration 27.31 16.82 13 15630 425282 110148374
Blindness 26.32 16.82 29 15614 36330 110537326
Eye complication associated with device 25.66 16.82 5 15638 72 110573584
Hypotony of eye 25.59 16.82 7 15636 468 110573188
Eye pruritus 25.23 16.82 27 15616 32748 110540908
Product substitution issue 25.20 16.82 23 15620 23038 110550618
Blindness unilateral 24.55 16.82 16 15627 9770 110563886
Conjunctival follicles 24.13 16.82 4 15639 21 110573635
Conjunctival hyperaemia 23.68 16.82 13 15630 5818 110567838
Abdominal discomfort 23.45 16.82 114 15529 393744 110179912
Maternal exposure during pregnancy 23.29 16.82 4 15639 254879 110318777
Scleral hyperaemia 23.24 16.82 6 15637 321 110573335
Arthropathy 23.23 16.82 6 15637 287516 110286140
Conjunctival scar 22.80 16.82 6 15637 346 110573310
Cardioactive drug level increased 22.52 16.82 11 15632 3871 110569785
Nasopharyngitis 21.14 16.82 15 15628 394346 110179310
Infusion related reaction 21.09 16.82 14 15629 381148 110192508
Joint swelling 21.04 16.82 19 15624 442826 110130830
Foreign body sensation in eyes 21.02 16.82 10 15633 3324 110570332
Growth of eyelashes 20.98 16.82 5 15638 192 110573464
Arthralgia 20.85 16.82 50 15593 779582 109794074
Wound 20.73 16.82 4 15639 234433 110339223
Eye inflammation 20.61 16.82 14 15629 9157 110564499
Angle closure glaucoma 20.56 16.82 10 15633 3489 110570167
Uveitis 20.56 16.82 20 15623 21690 110551966
Product quality issue 20.29 16.82 38 15605 77261 110496395
No adverse event 20.27 16.82 37 15606 73802 110499854
Product delivery mechanism issue 19.77 16.82 5 15638 246 110573410
Gastrointestinal disorder 19.63 16.82 5 15638 241947 110331709
Cystoid macular oedema 19.51 16.82 9 15634 2791 110570865
Erythema of eyelid 19.49 16.82 10 15633 3905 110569751
Retinal vascular occlusion 19.37 16.82 6 15637 622 110573034
Visual impairment 19.36 16.82 52 15591 134376 110439280
Drug ineffective 19.07 16.82 311 15332 1520229 109053427
Macular oedema 18.99 16.82 12 15631 6954 110566702
Corneal opacity 18.92 16.82 7 15636 1244 110572412
Hepatic enzyme increased 18.84 16.82 11 15632 320881 110252775
Pericarditis 18.83 16.82 4 15639 219110 110354546
Glaucoma surgery 18.21 16.82 4 15639 106 110573550
Vitreous haemorrhage 17.94 16.82 10 15633 4610 110569046
Conjunctivitis 17.93 16.82 23 15620 33769 110539887
Tracheobronchitis bacterial 17.90 16.82 3 15640 17 110573639
Infection 17.85 16.82 15 15628 362185 110211471
Conjunctival oedema 17.44 16.82 7 15636 1549 110572107
Bradycardia 17.43 16.82 55 15588 155462 110418194
Urticaria 17.25 16.82 12 15631 318845 110254811
Glossodynia 17.24 16.82 5 15638 221999 110351657
Eczema eyelids 17.14 16.82 5 15638 422 110573234
Febrile neutropenia 17.03 16.82 12 15631 316755 110256901
Abdominal pain 17.03 16.82 29 15614 512960 110060696
Hyperaemia 16.96 16.82 9 15634 3764 110569892
Corneal perforation 16.89 16.82 6 15637 950 110572706

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC S01EC03 SENSORY ORGANS
OPHTHALMOLOGICALS
ANTIGLAUCOMA PREPARATIONS AND MIOTICS
Carbonic anhydrase inhibitors
ATC S01EE52 SENSORY ORGANS
OPHTHALMOLOGICALS
ANTIGLAUCOMA PREPARATIONS AND MIOTICS
Prostaglandin analogues
FDA MoA N0000000235 Carbonic Anhydrase Inhibitors
FDA EPC N0000175517 Carbonic Anhydrase Inhibitor
MeSH PA D000959 Antihypertensive Agents
MeSH PA D002257 Carbonic Anhydrase Inhibitors
MeSH PA D002317 Cardiovascular Agents
MeSH PA D004791 Enzyme Inhibitors
CHEBI has role CHEBI:23018 EC 4.2.1.1 (carbonic anhydrase) inhibitor
CHEBI has role CHEBI:35674 antihypertensive agent
CHEBI has role CHEBI:39456 antiglaucoma drug
CHEBI has role CHEBI:66981 ophthalmology drug

Related Drugs by ATC class:

S01EC Carbonic anhydrase inhibitors 4 drugs
acetazolamidebrinzolamidedichlorphenamidemethazolamide
S01EE Prostaglandin analogues 6 drugs
bimatoprostlatanoprostlatanoprostene bunodnetarsudiltafluprosttravoprost

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Ocular hypertension indication 4210003 DOID:9282
Open-angle glaucoma indication 84494001 DOID:1067
Bronchospasm contraindication 4386001
Complete atrioventricular block contraindication 27885002
Acute cerebrovascular insufficiency contraindication 29322000
Hyperthyroidism contraindication 34486009 DOID:7998
Anaphylaxis contraindication 39579001
Sinus bradycardia contraindication 49710005
General anesthesia contraindication 50697003
Acute nephropathy contraindication 58574008
Diabetes mellitus contraindication 73211009 DOID:9351
Pulmonary emphysema contraindication 87433001
Cardiogenic shock contraindication 89138009
Myasthenia gravis contraindication 91637004 DOID:437
Partial atrioventricular block contraindication 195039008
Decompensated cardiac failure contraindication 195111005
Hypoglycemic disorder contraindication 237630007
Pregnancy, function contraindication 289908002
Severe chronic obstructive pulmonary disease contraindication 313299006




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 7.73 acidic
pKa2 8.34 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Carbonic anhydrase 2 Enzyme INHIBITOR Ki 9.70 CHEMBL CHEMBL
Androgen receptor Nuclear hormone receptor IC50 7.19 CHEMBL
Carbonic anhydrase 1 Enzyme Ki 6.30 CHEMBL
Carbonic anhydrase 4 Enzyme Ki 7.37 CHEMBL
Carbonic anhydrase 9 Enzyme Ki 7.28 CHEMBL
Carbonic anhydrase 12 Enzyme Ki 8.46 CHEMBL
Carbonic anhydrase 5A, mitochondrial Enzyme Ki 7.38 CHEMBL
Carbonic anhydrase 5B, mitochondrial Enzyme Ki 7.48 CHEMBL
Carbonic anhydrase 7 Enzyme Ki 8.46 CHEMBL
Carbonic anhydrase 3 Enzyme Ki 5.10 CHEMBL
Carbonic anhydrase 14 Enzyme Ki 7.57 CHEMBL
Carbonic anhydrase 13 Enzyme Ki 7.74 CHEMBL
Carbonic anhydrase 6 Enzyme Ki 8 CHEMBL
Carbonic anhydrase Enzyme Ki 5.37 CHEMBL
Androgen receptor Transcription factor Ki 7.96 CHEMBL
Carbonic anhydrase 13 Enzyme Ki 7.74 CHEMBL
Carbonic anhydrase 4 Enzyme Ki 7.37 CHEMBL
Carbonic anhydrase Enzyme Ki 6.39 CHEMBL
Carbonic anhydrase Enzyme Ki 4.51 CHEMBL
Carbonic anhydrase 15 Enzyme Ki 7.21 CHEMBL
Carbonic anhydrase Enzyme Ki 6.96 CHEMBL
Carbonic anhydrase Enzyme Ki 8.05 CHEMBL
Probable transmembrane carbonic anhydrase (Carbonate dehydratase) (Carbonic dehydratase); Transmembrane carbonic anhydrase Enzyme Ki 6.86 CHEMBL
Carbonic anhydrase Enzyme Ki 5.18 CHEMBL
Alpha carbonic anhydrase Enzyme Ki 7.74 CHEMBL
Carbonic anhydrase Enzyme Ki 6.95 CHEMBL
Carbonic anhydrase 2 Enzyme Ki 5.08 CHEMBL
Astrosclerin-3 Enzyme Ki 6.55 CHEMBL
Beta-carbonic anhydrase 1 Enzyme Ki 6.13 CHEMBL
Delta carbonic anhydrase Enzyme Ki 7.30 CHEMBL
Carbonic anhydrase 2 Enzyme Ki 7 CHEMBL
Carbonic anhydrase Enzyme Ki 6.56 CHEMBL
Carbonic anhydrase, alpha family Enzyme Ki 8.15 CHEMBL
Carbonate dehydratase Enzyme Ki 8.10 CHEMBL

External reference:

IDSource
4023982 VUID
N0000021987 NUI
D00653 KEGG_DRUG
130693-82-2 SECONDARY_CAS_RN
4020910 VANDF
4023982 VANDF
C0165590 UMLSCUI
CHEBI:4702 CHEBI
ETS PDB_CHEM_ID
CHEMBL218490 ChEMBL_ID
CHEMBL1201162 ChEMBL_ID
DB00869 DRUGBANK_ID
C062765 MESH_SUPPLEMENTAL_RECORD_UI
5284549 PUBCHEM_CID
6810 IUPHAR_LIGAND_ID
6960 INN_ID
9JDX055TW1 UNII
236065 RXNORM
158838 MMSL
29194 MMSL
4634 MMSL
004998 NDDF
004999 NDDF
108834004 SNOMEDCT_US
126154004 SNOMEDCT_US
373447009 SNOMEDCT_US
9JDX055TW1 INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Dorzolamide Hydrochloride Human Prescription Drug Label 1 14445-404 SOLUTION/ DROPS 20 mg OPHTHALMIC ANDA 24 sections
DORZOLAMIDE HYDROCHLORIDE TIMOLOL MALETAE Human Prescription Drug Label 2 14445-405 SOLUTION/ DROPS 20 mg OPHTHALMIC ANDA 24 sections
COSOPT PF HUMAN PRESCRIPTION DRUG LABEL 2 17478-604 SOLUTION/ DROPS 20 mg OPHTHALMIC NDA 26 sections
COSOPT HUMAN PRESCRIPTION DRUG LABEL 2 17478-605 SOLUTION/ DROPS 20 mg OPHTHALMIC NDA 28 sections
Dorzolamide HCl HUMAN PRESCRIPTION DRUG LABEL 1 24208-485 SOLUTION/ DROPS 20 mg OPHTHALMIC ANDA 25 sections
Dorzolamide Hydrochloride and Timolol Maleate HUMAN PRESCRIPTION DRUG LABEL 2 24208-486 SOLUTION/ DROPS 20 mg OPHTHALMIC ANDA 25 sections
Dorzolamide Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 25021-006 SOLUTION/ DROPS 20 mg OPHTHALMIC ANDA 28 sections
Dorzolamide Hydrochloride Ophthalmic Solution HUMAN PRESCRIPTION DRUG LABEL 1 42571-141 SOLUTION/ DROPS 20 mg OPHTHALMIC ANDA 24 sections
Dorzolamide Hydrochloride and Timolol Maleate ophthalmic Solution HUMAN PRESCRIPTION DRUG LABEL 2 42571-147 SOLUTION/ DROPS 22.30 mg OPHTHALMIC ANDA 24 sections
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE HUMAN PRESCRIPTION DRUG LABEL 2 42571-382 SOLUTION/ DROPS 20 mg OPHTHALMIC ANDA 25 sections
Dorzolamide Hydrochloride Human Prescription Drug Label 1 46708-519 SOLUTION/ DROPS 20 mg OPHTHALMIC ANDA 24 sections
Dorzolamide Hydrochloride and Timolol Maleate Ophthalmic Solution Human Prescription Drug Label 2 46708-553 SOLUTION/ DROPS 20 mg OPHTHALMIC ANDA 24 sections
Dorzolamide Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 50090-1246 SOLUTION/ DROPS 20 mg OPHTHALMIC ANDA 24 sections
Dorzolamide HCl HUMAN PRESCRIPTION DRUG LABEL 1 50090-2406 SOLUTION/ DROPS 20 mg OPHTHALMIC ANDA 25 sections
Dorzolamide HCl HUMAN PRESCRIPTION DRUG LABEL 1 50090-2768 SOLUTION 20 mg OPHTHALMIC ANDA 25 sections
Dorzolamide HCl and Timolol Maleate HUMAN PRESCRIPTION DRUG LABEL 2 50090-2867 SOLUTION 20 mg OPHTHALMIC ANDA 26 sections
Dorzolamide Hydrochloride Ophthalmic HUMAN PRESCRIPTION DRUG LABEL 1 50090-4882 SOLUTION/ DROPS 20 mg OPHTHALMIC ANDA 24 sections
Dorzolamide Hydrochloride and Timolol Maleate HUMAN PRESCRIPTION DRUG LABEL 2 50090-6371 SOLUTION/ DROPS 20 mg OPHTHALMIC ANDA 25 sections
Dorzolamide Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 50383-232 SOLUTION/ DROPS 20 mg OPHTHALMIC ANDA 24 sections
Dorzolamide Hydrochloride and Timolol Maleate HUMAN PRESCRIPTION DRUG LABEL 2 50383-233 SOLUTION/ DROPS 20 mg OPHTHALMIC ANDA 24 sections
Dorzolamide Hydrochloride and Timolol Maleate HUMAN PRESCRIPTION DRUG LABEL 2 50383-261 SOLUTION/ DROPS 20 mg OPHTHALMIC NDA 24 sections
Dorzolamide hydrochloride and timolol maleate HUMAN PRESCRIPTION DRUG LABEL 2 50742-323 SOLUTION/ DROPS 20 mg OPHTHALMIC ANDA 24 sections
Cosopt HUMAN PRESCRIPTION DRUG LABEL 2 54868-4279 SOLUTION 20 mg OPHTHALMIC NDA 26 sections
Dorzolamide Hydrochloride and Timolol Maleate HUMAN PRESCRIPTION DRUG LABEL 2 54868-5982 SOLUTION/ DROPS 20 mg OPHTHALMIC ANDA 23 sections
Dorzolamide HCl HUMAN PRESCRIPTION DRUG LABEL 1 54868-6330 SOLUTION/ DROPS 22.30 mg OPHTHALMIC ANDA 22 sections
Dorzolamide and Timolol HUMAN PRESCRIPTION DRUG LABEL 2 55545-1007 SOLUTION 20 mg OPHTHALMIC ANDA 1 sections
Dorzolamide hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 55545-1008 SOLUTION 20 mg OPHTHALMIC ANDA 1 sections
DORZOLAMIDE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 61314-019 SOLUTION/ DROPS 20 mg OPHTHALMIC ANDA 26 sections
Dorzolamide Hydrochloride and Timolol Maleate HUMAN PRESCRIPTION DRUG LABEL 2 61314-030 SOLUTION 20 mg OPHTHALMIC ANDA 24 sections
Dorzolamide Hydrochloride Human Prescription Drug Label 1 62332-519 SOLUTION/ DROPS 20 mg OPHTHALMIC ANDA 24 sections